What is HC Wainwright’s Forecast for CTXR Q1 Earnings?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – HC Wainwright issued their Q1 2025 earnings per share estimates for Citius Pharmaceuticals in a research note issued on Tuesday, November 12th. HC Wainwright analyst V. Bernardino expects that the company will post earnings per share of ($0.05) for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Citius Pharmaceuticals’ current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS and FY2026 earnings at $0.05 EPS.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its earnings results on Monday, August 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01).

Citius Pharmaceuticals Price Performance

CTXR stock opened at $0.39 on Wednesday. Citius Pharmaceuticals has a 1 year low of $0.31 and a 1 year high of $1.07. The firm has a 50-day moving average of $0.44 and a 200 day moving average of $0.61.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CTXR. BNP Paribas Financial Markets grew its stake in Citius Pharmaceuticals by 88.5% in the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock worth $62,000 after purchasing an additional 32,686 shares during the period. Point72 DIFC Ltd bought a new stake in shares of Citius Pharmaceuticals during the 2nd quarter valued at $29,000. Arkadios Wealth Advisors grew its position in shares of Citius Pharmaceuticals by 33.3% in the 3rd quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock worth $100,000 after buying an additional 50,000 shares during the period. Wealth Advisory Solutions LLC increased its stake in shares of Citius Pharmaceuticals by 33.1% in the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock worth $101,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Citius Pharmaceuticals by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock valued at $6,286,000 after acquiring an additional 104,889 shares during the period. Institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.